MedTrace Logo

Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPD

NCT01915784 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2015-05-29

No results posted yet for this study

Summary

Preference study: Genuair® (Pressair™) vs Breezhaler® (Neohaler™) inhalers in patients with COPD

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DEVICE

Genuair®

Inhaler with placebo only. Once daily, for 14 days.

DEVICE

Breezhaler®

Inhaler with placebo only. Once daily, for 14 days.

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • Almirall, S.A.

    lead INDUSTRY

Principal Investigators

  • Jordi Estruch, MD · Almirall, S.A.

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • Germany
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01915784 on ClinicalTrials.gov